373 related articles for article (PubMed ID: 18476929)
1. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T
J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
[TBL] [Abstract][Full Text] [Related]
2. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.
Nomura Y; Arata M; Koriyama C; Masuda K; Morita Y; Hazeki D; Ueno K; Eguchi T; Kawano Y
J Pediatr; 2010 May; 156(5):786-91. PubMed ID: 20097355
[TBL] [Abstract][Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
4. Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease.
Sung RY; Ng YM; Choi KC; Mok GC; Cheng YW; Ho MH;
Pediatr Infect Dis J; 2006 Jun; 25(6):521-5. PubMed ID: 16732150
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease presenting as cervical lymphadenitis or deep neck infection.
Kao HT; Huang YC; Lin TY
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):468-70. PubMed ID: 11283510
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
Singh-Grewal D; Wong M; Isaacs D
J Paediatr Child Health; 2005; 41(9-10):495-9. PubMed ID: 16150066
[TBL] [Abstract][Full Text] [Related]
9. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
10. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
13. Kawasaki disease in a pediatric intensive care unit: a case-control study.
Dominguez SR; Friedman K; Seewald R; Anderson MS; Willis L; Glodé MP
Pediatrics; 2008 Oct; 122(4):e786-90. PubMed ID: 18809597
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
[TBL] [Abstract][Full Text] [Related]
15. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features of recurrent Kawasaki disease in 20 children].
Zou LX; Gong FQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):617-9. PubMed ID: 18947484
[TBL] [Abstract][Full Text] [Related]
17. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Kawasaki disease in older children.
Cai Z; Zuo R; Liu Y
Clin Pediatr (Phila); 2011 Oct; 50(10):952-6. PubMed ID: 21628347
[TBL] [Abstract][Full Text] [Related]
19. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
20. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S; Safari M; Amin R
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
